MAY 30, 2014 07:30 AM PDT
Multiplexed Fusion Gene Detection using Next Generation Sequencing
Presented at the Clinical Diagnostics and Research Virtual Event
82 52 2389

Speakers:
  • Kelli Bramlett, Senior Manager, R&D Thermo Fisher Scientific Jeoffrey Schageman, Staff Scientist, Thermo Fisher Corp.
    Biography
      Kelli Bramlett leads the RNA Sequencing Applications Team at Life Sciences Solutions, Thermo Fisher Scientific. She guides the Research and Development effort focused on creating innovation sequencing and data analysis solutions for the detailed analysis of RNA. Prior to joining Thermo Fisher Scientific, Ms. Bramlett was a drug development scientist at Ely Lilly and Company where she led a team of scientists specializing in gene regulation and nuclear receptor biology to identify novel drug targets. Ms. Bramlett built her background and experience in gene regulation through prior academic positions at Baylor College of Medicine and M.D. Anderson Cancer Center. Kelli holds an undergraduate degree in Chemistry from Rice University in Houston, TX and a Masters Degree in Pharmacology from Indiana University School of Medicine in Indianapolis, IN.

      Jeoffrey Schageman is a staff scientist in the RNA Sequencing Applications Team at Life Sciences Solutions, Thermo Fisher Scientific. He specializes in the development and implementation analytical methods for NGS and gene expression analysis.   Jeoffrey typically leads the teams responsible for building analytical pipelines. The resulting pipelines provide analytical frameworks to enable other scientists to derive biological insight from seemingly insurmountable volumes of RNA sequence data.  Jeoffrey began his career in academia working on the Human Genome Project at UT Southwestern Medical Center in Dallas, then changed directions to focus on the bioinformatics of genome wide association studies in large cohorts to catalogue genetic variants related to cardiomyopathies. Mr. Schageman received his training in molecular biology and genetics from the University of North Texas.
       

    Abstract:
    As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing (or RNA-seq) for their gene expression analysis needs. RNA-seq goes beyond differential gene expression to provide fundamental insights into how genomes are organized and regulated. New RNA-seq solutions now offer higher sensitivity, increased sample number flexibility, and the ability to analyze highly degraded or rare samples from as little as 10 ng of input RNA. Dr. Bramlett will discuss how NGS and RNA-seq can be applied for the discovery of new tumor biomarkers in archived formalin-fixed, paraffin-embedded (FFPE) samples.

    Show Resources
    Loading Comments...